Pharmacotherapy of alcohol withdrawal: update and new developments

被引：4
|
作者：
Soyka, Michael [1 ,2 ]
Roesner, Susanne [3 ]
机构：
[1] Med Pk Chiemseeblick, Rasthausstr 25, D-83233 Bernau Felden, Germany
[2] LMU Munchen, Psychiat Univ Klin, Munich, Germany
[3] Forel Klin, Ellikon An Der Thur, Switzerland
来源：
NERVENARZT | 2021年 / 92卷 / 01期
关键词：
Alcohol use disorders; Anti-Craving-Drugs; Relapse; Acamprosate; Naltrexone; HIGH-DOSE BACLOFEN; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; USE DISORDERS; DEPENDENT PATIENTS; DRINKING PROBLEMS; SODIUM OXYBATE; EFFICACY; NALTREXONE; NALMEFENE;
D O I：
10.1007/s00115-020-00954-5
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
So far few medications are approved for prophylactic treatment of alcohol dependence relapse. Apart from disulfiram, which is no longer marketed in Germany, the opioid antagonists naltrexone, nalmefene and the putative glutamate antagonist acamprosate are approved. In some other countries, baclofen and gamma-hydroxybutyrate (GHB) are licensed. Possible other drugs of interest for prophylaxis of alcohol dependence relapse are vareniclin, gabapentin, and topiramate, but so far none of them have received approval. In the light of the currently running revision of the German guidelines for the diagnosis and treatment of alcohol related disorders, an update on the pharmacotherapy of alcohol dependence is presented.
引用
收藏
页码：57 / 65
页数：9
相关论文
共 50 条
12345